Hi spyglass, have enjoyed your posts over many years.
Because of the confidentiality terms associated with the Simcere glioblastoma milestone licence agreement for paxalisib, I can only assume that Kazia management would have made the first milestone payment conditional on the commencement of dosing for the first patient in Greater China recruited in the GBM AGILE study, which could be as early as the next few months.
Management has been relatively quiet over the last 8 months with regards to new deal announcements for paxalisib (drug in phase3) I can only assume that negotiations are ongoing with pharma and required confirmation of recent data releases for Glioblastoma and DMG/DIPG. That might also explain why management has not purchased additional Kazia shares at the 52 week lows.
The Government research rebate refund is due to be banked later this year
IMO, Kazia's future prospects have never been better.
Regards.
KZA Price at posting:
66.0¢ Sentiment: Buy Disclosure: Held
